NCT05118919 - A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Ulcerative Colitis

Interventions

BIOLOGICAL

BGP-014

Oral capsule containing lyophilised Lactobacillus reuteri

BIOLOGICAL

Placebo

Oral capsule

Trial Locations (4)

Department of Gastroenterology and Hepatology, Linköping University Hospital, Linköping

Gastroenterology Department, Danderyds Hospital, Stockholm

Gastroenterology Department, Ersta Hospital, Stockholm

Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital, Uppsala